Key Highlights
- Earnings per share were USD 0.01, against an estimate of a USD 0.08 loss.
- Net income was USD 2.47 million, versus a net loss of USD 4.54 million.
- Loss from operations widened to USD 4.48 million from USD 2.49 million.
- Cash and cash equivalents were USD 11.4 million at September 30, 2026.
AEON Biopharma (NYSE American:AEON) moved from loss to profit in the third quarter of 2026, reporting Net Income of USD 2.47 million against a net loss of USD 4.54 million a year earlier. Basic and diluted net income per share attributable to common stockholders was USD 0.01, compared with a loss of USD 0.39, and the estimate had been a loss of USD 0.08.
The profit owed much to a USD 7.01 million gain from the change in Fair Value of warrants. No Revenue was recorded in either period, and the underlying operations remained loss-making.
Operating Costs Moved Higher
Selling, general and administrative expenses were USD 2.99 million, compared with USD 1.93 million, an increase that management's discussion put at USD 1.1 million, or 55%. Research and Development expenses were USD 1.52 million, compared with USD 597 thousand. Contingent consideration produced a fair value Credit of USD 22 thousand, against a credit of USD 37 thousand.
Total operating costs and expenses were USD 4.48 million, against USD 2.49 million, and the loss from operations equaled those totals. Weighted average shares of common stock outstanding were 89,957,587, compared with 11,634,946.
Non-Operating Items and the Nine Months
The change in fair value of convertible notes was a loss of USD 214 thousand, compared with a loss of USD 1.88 million, and other income, net, was USD 148 thousand. Total other income, net, was USD 6.95 million, against a loss of USD 2.05 million, and income before taxes was USD 2.47 million.
Across the nine months ended September 30, 2026, the loss from operations was USD 16.34 million, compared with USD 7.29 million. Selling, general and administrative expenses were USD 9.88 million and research and development expenses were USD 6.49 million. The company booked a USD 16.61 million gain on the change in fair value of warrants, against USD 85.95 million before, along with a USD 9.15 million loss on convertible notes and a USD 1.74 million loss on a derivative liability. The net loss was USD 10.48 million, compared with USD 2.09 million, and net loss per share was USD 0.17, compared with USD 0.23.
Balance Sheet and Going Concern Doubt
Cash and cash equivalents were USD 11.42 million at September 30, 2026, up from USD 3.01 million at December 31, 2025. Total Assets were USD 14.13 million, compared with USD 5.56 million, and total current liabilities were USD 4.57 million, compared with USD 6.90 million. Total liabilities fell to USD 11.74 million from USD 60.59 million. Additional paid-in Capital stood at USD 483.67 million, and the accumulated Deficit at USD 481.30 million.
According to the filing, development work centres on ABP-450, and the company expects losses and cash outflows from operations to persist for the foreseeable future. It also discloses substantial doubt about the company's going concern status, including its capacity to meet obligations that come due within a year of the financial statements being issued.






Please wait processing your request...